



<p>PTO-1449 REPRODUCED</p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</p> <p>January 21, 2005</p> <p>(Use several sheets if necessary)</p>	ATTORNEY DOCKET NO. 3298.1001-000	APPLICATION NO. 10/072,611
	FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 8, 2002
	EXAMINER Cheu, Changhwa J:	CONFIRMATION NO. 1456

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW Ratain, M.J., et al., "Phase I Study of Amonafide Dosing Based on Acetylator Phenotype," *Cancer Res.*, 53:2304-2308 (1993).



EXAMINER		DATE CONSIDERED	3/15/05
----------	---	-----------------	---------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 22, 2004 MAR 24 2004 U.S. Patent & Trademark Office (use several sheets if necessary)		ATTORNEY DOCKET NO. 3298.1001-000	APPLICATION NO. 10/072,611
		FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 8, 2002
		EXAMINER C.J. Cheu	CONFIRMATION NO. 1456
			GROUP 1641

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
J	LA	5,830,672	11-03-1998	Wainer <i>et al.</i>

FOREIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
J	AL	WO 00/55624 A2	09-21-2000	Brian Leyland-Jones
J	AM	EP 0921396 A2	06-09-1999	Pfizer Products Inc.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
J	AR	Tang, B.K., <i>et al.</i> , "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," <i>Clinical Pharmacology & Therapeutics</i> , 49(6): 648-657 (1991).
J	AS	Kroemer, H.K. and Eichelbaum, M., "'It's the Genes, Stupid'. Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," <i>Life Sciences</i> , 56(26): 2285-2298 (1995).
J	AT	Wong, P., <i>et al.</i> , "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of N-acetyltransferase (NAT2) Phenotypes," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 13(9): 1079-1086 (1995).
J	AU	Wong, P., <i>et al.</i> , "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," Proceedings of the 90th Annual Meeting of the American Association for Cancer Research, 40:53 (1999).
J	AV	Wolf, C.R. and Smith, G., "Chapter 18. Cytochrome P450 CYP2D6," <i>Metabolic Polymorphisms and Susceptibility to Cancer</i> , 148:209-229 (1999).

EXAMINER 	DATE CONSIDERED 3/15/2005
---	------------------------------